This is a single-arm, non-randomized feasibility and Phase I trial of 20(S) Camptothecin Propionate administered orally. CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohorts of 3+3 patients will be treated. CZ48 will be administered orally daily (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink up to one gallon of fluid daily if possible to flush the bladder to mitigate cystitis. Cystitis is an anticipated toxicity as CZ48 is a pro-drug of CPT (Camptothecin)

开始日期2008-07-01

申办/合作机构

Cao Pharmaceuticals, Inc.初创企业

[+1]

100 项与 Cao Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Cao Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Cao Pharmaceuticals, Inc. 相关的文献（医药）

2020-02-01·Journal of pharmaceutical and biomedical analysis

The development and validation of an LC-MS/MS method for the quantification of CZ112, a prodrug of 9-Nitrocamptothecin in rat plasma

Article

作者: Kou, Xiaohan ; Zhang, Qiang ; Hu, Zhiwei ; Wang, Yang ; Cao, Zhisong ; Shao, Changmin ; Yu, Tao ; Wang, Ziming ; Zheng, Jian ; Wang, Zijia

9-Nitrocamptothecin-20-O-propionate (CZ112) and 9-Nitrocamptothecin (9NC) are the bioactive derivatives of camptothecin (CPT), an alkaloid isolated from Camptotheca acuminata, and have been confirmed to possess high anti-cancer properties. In the present study, 9NC was identified as the major metabolite of CZ112 in rat plasma through HPLC/photodiode array detection (PDA) and liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis. A highly sensitive LC-MS/MS method was developed and validated for the simultaneous analysis of CZ112 and 9NC in rat plasma, and camptothecin-20-O-acetate (CZ44) was used as an internal standard (IS). The calibration curves were linear (r² > 0.999) over concentrations from 2.5 to 320 ng/mL for both CZ112 and 9NC. The method had an accuracy of 96.7-109.6%, and the intra- and inter-day precision (RSD%) were 10.9% or less for CZ112 and 9NC. The stability data showed no significant degradation occurred under the experimental conditions. This method was successfully applied to the pharmacokinetic study of CZ112 and its metabolite 9NC in rat plasma after intravenous and intragastric administration. The oral bioavailability of CZ112 was 6.2 ± 3.3% (n = 6).

100 项与 Cao Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Cao Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息